

13. Use according to claim 10 wherein the cells expressing human cytochrome P450 2D6 are contacted with the substance to be tested.

14. Method for screening of substances with respect to their metabolization by human cytochrome P450 2D6 wherein the cells of the test system according to claim 1 are contacted with a substance and the metabolic product is measured.

15. Method for the detection of novel *P450 2D6* alleles wherein said method comprises the heterologous expression of the allele in question in a cell, testing the cells expressing the allele in question with respect to the cytochrome P450 2D6-dependent metabolism of one or more compounds and comparison of the metabolism of the cells to the metabolism of cells of the test system according to claim 1.

18. Method according to claim 16 wherein emulgen 913 is added in a final concentration of 0.25% (w/v).

REMARKS


The amendments merely change the dependencies of the claims, and thus do not constitute new matter and are not amendments for purposes of patentability.

If there are any questions or comments regarding this Preliminary Amendment, the Examiner is encouraged to contact the undersigned agent as indicated below.

Respectfully submitted,

Date:

11/9/01



David S. Harper
Registration No. 42,636

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen
Hulbert & Berghoff, Ltd.
300 South Wacker Drive
Chicago, IL 60606

MARKED UP VERSION OF THE AMENDMENTS

Please amend the claims as follows:

5. Test system according to [any one of] claim[s] 1 [to 4] wherein said cells are Chinese hamster lung fibroblasts or cells derived therefrom.
8. Test system according to [any of the] claim[s] 1 [to 7] wherein said cells express cDNA.
9. Kit comprising the test system according to [any of the] claim[s] 1 [to 8].
10. Use of the test system according to [any of the] claim[s] 1 [to 8] for the study of the gene-dependent toxicity of metabolites.
12. Use of the test system according to [any of the] claim[s] 1 [to 8] for determining a toxic, mutagenic or cancerogenous effect of compounds.
13. Use according to [any one of] claim[s] 10 [to 12] wherein the cells expressing human cytochrome P450 2D6 are contacted with the substance to be tested.
14. Method for screening of substances with respect to their metabolization by human cytochrome P450 2D6 wherein the cells of the test system according to [any of the] claim[s] 1 [to 8] are contacted with a substance and the metabolic product is measured.
15. Method for the detection of novel *P450 2D6* alleles wherein said method comprises the heterologous expression of the allele in question in a cell, testing the cells expressing the allele in question with respect to the cytochrome P450 2D6-dependent metabolism of one or more compounds and comparison of the metabolism of the cells to the metabolism of cells of the test system according to [any one of] claim[s] 1 [to 8].
18. Method according to claim 16 [or 17] wherein emulgen 913 is added in a final concentration of 0.25% (w/v).